NASDAQ GS | VYGR (Common Stock)


 0.4 (3.21%)

Data as of: 10/27/16  4:00 p.m. ET

Investor Overview

Corporate Profile

Voyager Therapeutics is developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system. Our founders include scientific and clinical leaders in the fields of adeno-associated virus (AAV) gene therapy, expressed RNA interference and neuroscience. Our management team has deep expertise and a track record of building exceptional life science companies. More >>

Recent NewsMore >>
October 18, 2016
Voyager Therapeutics Announces Planned Transition Process for Chief Financial Officer
September 15, 2016
Voyager Therapeutics Licenses Novel Gene Therapy Capsids from the California Institute of Technology
September 12, 2016
Voyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington’s Disease
Upcoming EventsMore >>
11/15/16 10:15 a.m. ET
Voyager Therapeutics Inc at Stifel 2016 Healthcare Conference
LocationNew York, NY
Voyager Therapeutics Inc at Piper Jaffray Healthcare Conference
LocationNew York, NY
Voyager Therapeutics Inc at BMO Prescriptions for Success Healthcare Conference
LocationNew York, NY
Data provided by Nasdaq. Minimum 15 minutes delayed.